Rovi’s Value-Added US Risperidone Gets New Goal Date, Teva Ruled Out As Partner
Follows Teva’s Recent Launch Of Rovi’s Xeplion Generic In Spain
Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.
You may also be interested in...
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.
Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.